Key Takeaways:
Rosen Law Firm has issued a final reminder to Inovio Pharmaceuticals (NASDAQ: INO) investors with losses over $100,000 to secure counsel before the April 7 lead plaintiff deadline in a securities class action lawsuit. The action alleges the biotechnology company made materially false and misleading statements regarding its product development and commercial prospects.
"We encourage investors to select qualified counsel with a track record of success in leadership roles," the Rosen Law Firm stated in a press release, highlighting its experience in securities class actions and noting that many firms that issue notices do not actually litigate the cases.
The lawsuit, filed in a U.S. court, covers investors who purchased Inovio securities between October 10, 2023, and December 26, 2025. According to the complaint, Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device and overstated the likelihood of its INO-3107 treatment receiving FDA accelerated approval. The firm alleges these actions artificially inflated the stock price, leading to significant investor losses when the true details emerged.
The case highlights the risks associated with biotech investments, where regulatory timelines and manufacturing capabilities are critical. The Rosen Law Firm has been active in this area, recently filing similar class actions against other life sciences companies such as Immutep Ltd. and ImmunityBio, Inc., citing misleading business information and overstated drug capabilities, respectively.
The core of the lawsuit against Inovio claims that the company was aware of, but did not disclose, significant issues that jeopardized its stated timelines. Specifically, the suit alleges that manufacturing for the CELLECTRA delivery device was deficient, making it unlikely that the company could submit its Biologics License Application (BLA) for INO-3107 to the FDA by the targeted second half of 2024.
Furthermore, the complaint argues that Inovio lacked sufficient data to justify eligibility for the FDA's accelerated approval or priority review pathways for INO-3107. As a result, the lawsuit contends that the company's public statements about the treatment's regulatory and commercial prospects were materially false and misleading. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation; however, an investor’s ability to share in any potential recovery is not dependent upon serving as lead plaintiff.
The outcome of this lawsuit could have significant financial implications for Inovio and may influence how biotech companies communicate their manufacturing and regulatory timelines to investors. Shareholders will be watching the court proceedings following the April 7 deadline for the selection of a lead plaintiff.
This article is for informational purposes only and does not constitute investment advice.
